Skip to search formSkip to main contentSkip to account menu

Glioblastoma Cancer Vaccine ERC1671

Known as: ERC-1671, ERC1671, Gliovac 
A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
HOUT-17. A PRELIMINARY DATA REPORT ON A PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA
2016
2016
ATIM-20. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS
2015
2015
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
Glioblastoma multiforme is a highy aggressive tumor that recurs despite resection, focal beam radiation, and temozolamide… 
2015
2015
A personalized immunotherapeutic vaccine (Gliovac Or ERC1671) against recurrent glioblastoma multiforme (GBM)
Patients suffering from a glioblastoma multiforme (GBM) present a very poor prognostic. GBM is the most malignant glioma with a… 
2012
2012
FIRST REPORT OF ERC-1671 (GLIOVAC) VACCINE USE IN GLIOBLASTOMA PATIENTS WITH RECURRENT DISEASE
Author(s): Bota, Daniela A; Pretto, Chrystel; Hantos, Peter; Hofman, Florence M; Chen, Thomas C; Carrillo, Jose A; Schijns… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)